Posatirelin

Summary

Posatirelin (RGH-2202, L-6-ketopiperidine-2-carbonyl-L-leucyl-L-prolinamide) is a synthetic TRH analogue investigated for its analeptic, neuroprotective, and neurostimulatory properties. It has been studied in the context of consciousness disorders, spinal muscular atrophy in children, and neurological recovery. Unlike native TRH, it has improved metabolic stability and CNS penetration.

Mechanism of Action

Synthetic tripeptide analogue of TRH that acts as a TRH receptor agonist, stimulating the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary; also exhibits central nervous system effects including analeptic and neuroprotective properties.

Routes of Administration

Goals & Uses

• Treatment of disorders of consciousnessNeurologicalLow
• Analeptic / arousal stimulationNeurologicalModerate
• NeuroprotectionNeurologyLow
• Treatment of spinal muscular atrophy (SMA)NeuromuscularLow
• TSH/prolactin stimulation (diagnostic)EndocrinologicalModerate

Contraindications

• Hypersensitivity to posatirelin or TRH analoguesAllergy/ImmunologicalHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Active epilepsy / seizure disorderNeurologicalModerate
• Uncontrolled hyperthyroidismEndocrinologicalHigh

Adverse Effects

• Transient blood pressure changesCardiovascularUncommon
• Urinary urgencyGenitourinaryUncommon
• FlushingVascularCommonWarmth and redness of the skin
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Increased TSH/prolactin levelsEndocrinologicalCommon

Drug Interactions

• Antiepileptic drugsModerate
• Thyroid hormones (T3/T4)Moderate
• Dopamine antagonists (antipsychotics)Low

Population Constraints

• Pregnant or lactating womenReproductiveRelative
• Pediatric patients (SMA context)AgeRelative
• Elderly patientsAgeRelative
• Patients with thyroid or pituitary diseaseDisease StateRelative

Regulatory Status

• European UnionInvestigationalStudied in European clinical trials (notably Italy) for neurological conditions; no marketing authorization granted.
• United StatesUnapprovedNot approved by the FDA for any indication; investigational use only.
• United KingdomUnapprovedNo approved status in the UK; remains a research compound.

Not approved by FDA, EMA, or other major regulatory agencies for any indication. Investigated in clinical trials in Europe (particularly Italy) during the 1990s–2000s for neurological indications. Currently remains an investigational/research compound.

Evidence & Sources

No sources recorded yet.